The Quigley Corporation has reported the results of a mouse multiple sclerosis (MS) model study that has shown that the QR-442, a naturally derived compound was found to delay onset of disease as well as considerably lowering severity.
QR-442 was studied in a series of murine (mouse) experiments at the Department of Molecular Genetics and Microbiology and Immunology at the University of Medicine and Dentistry of New Jersey. The anti-inflammatory effects of QR-442 were first evaluated in in-vitro experiments as well as in an immune-mediated inflammation model in mice. In this model inflammation is induced locally by a secondary, immune response to an antigen, which is known scientifically as delayed type hypersensitivity or DTH.
Because MS involves a classic example of a DTH reaction in the central nervous system, the effect of QR-442 was tested in an animal model for multiple sclerosis. Results showed that mice treated with QR-442 had a delayed onset of this disease and disease severity was considerably lower especially in animals receiving several doses of the compound.